Figure 2 | Scientific Reports

Figure 2

From: Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis

Figure 2

Adjusted results from CT-based body composition analysis (BCA) before (T0) and after (T1) elexacaftor/tezacaftor/ivacaftor (ETI) therapy. Estimated mean BCA outcome ratio (pre/post-ETI) by BMI category. Underweight pwCF (n = 20, BMI < 18.5 kg/m2) exhibited pronounced increase of TAT ratio (p = 0.013). Statistics: Generalized equation estimation models, estimated mean and standard deviation. P-value shown for interaction effect. Interaction effect time(pre/post)*BMI category adjusted for age at ETI start, biological sex and duration of ETI therapy. BMI, body mass index; TAT, total adipose tissue; IMAT, intra- and intermuscular adipose tissue; EAT, epicardial adipose tissue; PAT, paracardial adipose tissue; SAT, subcutaneous adipose tissue.

Back to article page